BCG immunotherapy for carcinoma of the urinary bladder
Art & Science Previous     Next

BCG immunotherapy for carcinoma of the urinary bladder

Susan Cumisky Nurse Practitioner, Urology, Yeovil District Hospital

Treatment of superficial bladder cancer using BCG as an immunotherapeutic agent has proved effective. Stringent safety procedures have been introduced at Yeovil District Hospital so that this treatment is available to patients with bladder cancer, while ensuring that other patients and staff are protected from the possibility of BCG cross-infection.

Nursing Standard. 14, 37, 45-47. doi: 10.7748/ns2000.05.14.37.45.c2849

Want to read more?

Subscribe for unlimited access

Try 1 month’s access for just £1 and get:

Your subscription package includes:
  • Full access to nursingstandard.com and the Nursing Standard app
  • The monthly digital edition
  • RCNi Portfolio and interactive CPD quizzes
  • RCNi Learning with 200+ evidence-based modules
  • 10 articles a month from any other RCNi journal
Subscribe
Already subscribed? Log in

Alternatively, you can purchase access to this article for the next seven days. Buy now

Or